Summary: Autism spectrum disorder (ASD) and intellectual disability (ID) can present with similar behaviors and even share identical genetic mutations, making early and accurate diagnosis difficult for pediatric neurologists. Because blood-based biomarkers are often unreliable for brain conditions due to the blood-brain barrier, clinicians usually depend on months or years of behavioral observation—delaying interventions during a critical early window. A new laboratory approach uses a carbon-fiber nanosensor to measure real-time nitric oxide (NO) production from patient-derived induced pluripotent stem cells (iPSCs), enabling a clear biochemical distinction between ASD and ID at a very early developmental stage.
Researchers demonstrated that this bio-electrochemical method can quantify nascent NO directly from undifferentiated iPSCs. The nanosensor detected substantially different NO baselines across cohorts—even when patient cell lines carried the exact same causative mutation—suggesting a path toward objective, precision diagnostics for neurodevelopmental disorders during infancy.
Key Facts
- Same Mutation, Different Outcome: The carbon-fiber nanosensor differentiated ASD from ID cellular signaling even when both patient-derived cell lines shared the identical genetic mutation.
- Nitric Oxide Readings: Real-time measurements showed clear, quantifiable differences: ID patient iPSCs produced approximately 11 nM NO, ASD patient iPSCs about 6 nM, and healthy control iPSCs about 65 nM.
- Bypassing the Blood-Brain Barrier: Using iPSCs instead of blood tests removes confounding influences imposed by the blood-brain barrier, such as age, diet, or medications, allowing a more direct assessment of brain-relevant biochemistry.
- Simplified Workflow: Measurements were taken from undifferentiated iPSCs, so the protocol does not require time-consuming neuronal differentiation, shortening turnaround and lowering complexity.
- Potential for Earlier Diagnosis: Because somatic cells can be reprogrammed into iPSCs soon after birth, this approach could enable differential testing within months of life—well before behavioral signs fully emerge.
- Precision Medicine Framework: Though initial sample sizes were limited, the study establishes a reproducible laboratory template for applying biochemical precision diagnostics to complex neurodevelopmental disorders.
Source: KeAI Communications
Study overview: A study published in NeuroMarkers reports that a carbon-fiber nanosensor can measure nitric oxide from patient-derived iPSCs to distinguish autism spectrum disorder from intellectual disability, even when the same genetic mutation is present in both conditions. The research team, based in the Department of Chemistry and Biochemistry at Ohio University, adapted a nanosensor originally used in cardiovascular and Alzheimer’s research to monitor nascent NO production in real time. By focusing on iPSCs, the method directly assesses early developmental cellular chemistry without interference from peripheral blood factors.
Co-author Howard D. Dewald summarized the core finding: “ASD patient cells produced about 6 nM of NO, ID patient cells produced 11 nM, and healthy control cells produced 65 nM—a clear, quantifiable difference.” Co-author Abdullah Asif Khan emphasized that real-time bio-electrochemical analysis of newly generated nitric oxide can act as a functional biomarker, revealing differences that genetic sequencing alone cannot show.
The researchers used iPSCs because these cells model the earliest stages of human development and therefore avoid confounding variables such as chronological age, diet, or ongoing medications. Notably, the protocol recorded high-resolution NO signals from undifferentiated iPSCs, eliminating the need for cell differentiation into neurons and streamlining laboratory workflow.
Current diagnostic practice for ASD relies heavily on behavioral assessments, which can delay definitive diagnosis and treatment. This nanosensor-based biochemical approach has the potential to reduce that delay dramatically, enabling earlier therapeutic planning and individualized intervention.
Key Questions Answered
A: Genetic tests reveal a static blueprint, but two individuals with the same mutation can have different cellular behavior and developmental trajectories. The carbon-fiber nanosensor measures real-time cellular activity—specifically nanomolar levels of nitric oxide—which uncovers functional differences that do not appear on a genetic report. In this study, those functional NO differences aligned with distinct clinical diagnoses.
A: The blood-brain barrier separates peripheral blood chemistry from the central nervous system, so blood measures may not reflect brain-relevant biochemical states. Patient-derived iPSCs recreate early developmental cell states and provide a controlled system to monitor brain-relevant signals like NO without interference from the blood-brain barrier or external variables such as diet or medication.
A: Presently, diagnosing ASD or ID often requires prolonged behavioral observation, delaying targeted therapies. A reliable, objective biochemical test performed on somatic cells reprogrammed to iPSCs could yield a definitive differential diagnosis in infancy, allowing families and clinicians to start tailored interventions much earlier.
Editorial Notes
- This article was edited by a Neuroscience News editor.
- The journal paper was reviewed in full by the editorial team.
- Additional context was added by staff to clarify methods and clinical implications.
About this neurotech research news
Author: Ye He
Source: KeAI Communications
Contact: Ye He – KeAi Communications
Image: Image credit to Neuroscience News
Original Research: Open access. “Nanosensor-based method for autism diagnosis using nitric oxide from patient-derived induced pluripotent stem cells as a biomarker” by Abdullah Asif Khan and Howard D. Dewald. NeuroMarkers. DOI: 10.1016/j.neumar.2026.100166
Abstract
Nanosensor-based method for autism diagnosis using nitric oxide from patient-derived induced pluripotent stem cells as a biomarker
Objectives
ASD prevalence continues to rise globally, driving research into biomarkers that could enable earlier identification. Most candidate biomarkers do not address the diagnostic challenge posed when the same causative mutation produces different neurodevelopmental outcomes—such as ASD in one individual and intellectual disability in another. This study aimed to test whether neonatal nitric oxide production, measured from patient-derived iPSCs, could serve as a differential biomarker when the same mutation underlies different clinical diagnoses.
Methods
The team conducted real-time bio-electroanalytical experiments using a porphyrin-modified carbon-fiber nanosensor to measure nascent nitric oxide from iPSCs derived from three sources: an individual with autism, an individual with intellectual disability, and an unrelated healthy control. The disease model cell lines were selected to share the same causative mutation while having different neuropsychiatric diagnoses. Both the ASD and ID patients carried a rare de novo E198K mutation in the B56δ β-subunit of the protein phosphatase 2A enzyme; the control line had no neurodevelopmental or neurodegenerative diagnosis.
Results
Measurements revealed that ASD iPSCs produced approximately 6 nM NO, ID iPSCs produced approximately 11 nM NO, and healthy control iPSCs produced approximately 65 nM NO—demonstrating robust, quantifiable differences in nascent nitric oxide production across the three groups.
Conclusion
The study shows that despite shared genetic causes and overlapping symptoms among neurodevelopmental disorders, functional biochemical readouts—specifically newborn nitric oxide production measured by carbon-fiber porphyrinic nanosensors—can serve as an objective biomarker for both diagnosis and differential diagnosis of autism. This approach paves the way toward earlier, precision-guided interventions and a scalable laboratory method to apply biochemical diagnostics in neurodevelopmental care.